Article Text

Download PDFPDF
Case report
Double valve involvement: papillary fibroelastoma in a patient with severe mitral and aortic valve regurgitation
  1. Oyintayo Ajiboye,
  2. Jan Michael Racoma,
  3. Kifah Hussain and
  4. Benjamin Mba
  1. Medicine, John H Stroger, Jr Hospital of Cook County, Chicago, Illinois, USA
  1. Correspondence to Dr Benjamin Mba; bmba{at}cookcountyhhs.org

Abstract

Cardiac papillary fibroelastoma is a benign neoplasm that arises in the endocardium. It commonly presents as an incidental finding on transthoracic echocardiography or as emboli to the coronary, cerebral or pulmonary vasculature. Clinical manifestations described in the literature have generally been related to a sequelae of the associated embolic phenomenon of these lesions. Valve regurgitation is less common with papillary fibroelastoma and when found, it is not known to cause severe regurgitation requiring valve replacement. We report a case of papillary fibroelastoma in a patient with severe mitral and aortic valve regurgitation in association with mobile masses requiring double valve replacement. This patient managed initially as infective endocarditis with severe double valve regurgitation, was found to have valvular masses concernng for papillary fibroelastoma and subsequently confirmed on pathology.

  • cardiothoracic surgery
  • valvar diseases
  • cardiovascular system

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors OA: wrote the case presentation, introduction, abstract and edited the manuscript; JMR: wrote the introduction and discussion; KH: provided the images and edited the manuscript and BM: critically reviewed and edited the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.